Categories: Market Research

Ovulation Inducing Drugs Market Size and Forecast 2024-2033|Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Abbvie Inc., Novartis AG

The Ovulation Inducing Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Ovulation Inducing Drugs Market:

https://www.thebusinessresearchcompany.com/report/ovulation-inducing-drugs-global-market-report

According to The Business Research Company’s Ovulation Inducing Drugs Global Market Report 2024, The ovulation inducing drugs market size has grown strongly in recent years. It will grow from $4.11 billion in 2023 to $4.42 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to development of clomiphene citrate, introduction of letrozole, regulatory approvals and standardization, emergence of ovulation predictor kits.

The ovulation inducing drugs market size is expected to see strong growth in the next few years. It will grow to $5.7 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to changing lifestyles and delayed childbearing, digital health integration, expanding market reach, rising infertility rates, customized treatment regimens.. Major trends in the forecast period include personalized treatment approaches, advancements in reproductive endocrinology, non-invasive fertility monitoring, rising demand for assisted reproductive technologies, development of novel drug formulations.

The increasing prevalence of women’s infertility is expected to propel the growth of the ovulation-inducing drug market. Women’s infertility refers to the biological condition in which a woman cannot conceive a pregnancy or carry it to full term despite engaging in regular, unprotected sexual intercourse for an extended period, typically around a year or more. Ovulation-inducing drugs are used to treat women’s infertility to address irregular or absent ovulation issues. These drugs target the hormonal pathways involved in the ovulation process and stimulate the ovaries to release mature eggs. For instance, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2022, there will be 6.1 million women between the ages of 15 and 44 in the US who have trouble becoming pregnant, equivalent to 10% of all women. Furthermore, in June 2022, according to CCRM Management Company LLC, a US medical management company, infertility affects 1 in 4 couples globally on average, rising by 5% to 10% each year. Therefore, the increasing prevalence of women’s infertility drives the growth of the ovulation-inducing drug market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=13256&type=smp

The ovulation inducing drugs market covered in this report is segmented –

1) By Drug Class: Hormones, Therapeutics Drugs

2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

3) By End-User: Hospital, Homecare, Specialty Clinics, Other End-Users

Major companies operating in the ovulation-inducing drugs market are developing innovative drugs such as Cetrorelix acetate and getting approval to treat women undergoing controlled ovarian stimulation. Cetrorelix acetate for injection (cetrorelix) is a gonadotropin-releasing hormone (GnRH) antagonist. It prevents premature ovulation in women undergoing in vitro fertilization (IVF). For instance, in August 2022, Akorn Operating Company LLC, a US-based pharmaceutical company, received FDA approval for a generic version of cetrorelix acetate for injection, 0.25 mg (Cetrorelix). This is the initial AP-rated bioequivalent Merck Serono Cetrotide variant that has been authorized. Cetrorelix acetate is a GnRH antagonist that acts by blocking the effects of the gonadotropin-releasing hormone (GnRH). GnRH promotes the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. Moreover, it is used to prevent premature LH surges in women undergoing controlled ovarian stimulation (COS) and to help ensure that all of the eggs have a chance to mature.

The ovulation inducing drugs market report table of contents includes:

1. Executive Summary

2. Ovulation Inducing Drugs Market Characteristics

3. Ovulation Inducing Drugs Market Trends And Strategies

4. Ovulation Inducing Drugs Market – Macro Economic Scenario

5. Global Ovulation Inducing Drugs Market Size and Growth

26. South America Ovulation Inducing Drugs Market

27. Brazil Ovulation Inducing Drugs Market

28. Middle East Ovulation Inducing Drugs Market

29. Africa Ovulation Inducing Drugs Market

30. Ovulation Inducing Drugs Market Competitive Landscape And Company Profiles

Top Major Players: